Peptide Reports

LL37

Community Protocol

LL37

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 5 MG and 10 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
5 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water2.5 mg/mLEach U-100 unit = 25 mcg
10 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water5 mg/mLEach U-100 unit = 50 mcg

Syringe Conversion

Reported amount5 MG setup10 MG setup
50 mcg2 units1 units
100 mcg4 units2 units
250 mcg10 units5 units
500 mcg20 units10 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
50-100 mcgOnce dailyLower-start reports
100-250 mcgOnce dailyMost recurring range
500 mcgDaily in some reportsHigher experimental use

Observations

  • Community discussions most often centered on innate-immunity, biofilm and persistent-infection research.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • Immune activation, inflammatory reactions and worsening symptoms are possible; infection concerns require qualified medical evaluation.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: LL37
  2. PubMed literature search: LL37